Formulate licensing strategies and negotiate the terms of an agreement
Develop a licensing strategy (which will include a financial strategy)
Discuss the key issues in a licence agreement and how the principles inter-relate
Understand how to negotiate the terms of a licence agreement
Know how to assess the risks of ‘less than favourable’ terms
Discuss successful and unsuccessful licensing case studies and identify what worked and what could have been improved
This online course also focuses on networking, providing a valuable platform to meet peers, discuss best practice, and interact with the course team and other contributors.
PLEASE NOTE: There may be a requirement for delegates to undertake some pre-course work/reading before the course begins.
Who should attend?
- Relevant job titles: Relevant to anyone working in KE
- Relevant sectors/organisations: Universities, funding bodies, industry
- Experience needed: 1-3 years’ experience in Technology Transfer, some experience of licensing (run a few smaller deals), a basic understanding on IP is beneficial
- Supporting courses: Fundamentals in Technology Transfer
Licensing is a common route for knowledge exchange, but the complexities can make this a slow and painful process. Licensing early-stage technology is often difficult. Universities in particular face unique challenges on the terms they can accept when licensing their IP that industry is not always aware of. This course will give the delegates the tools they need to better structure their licence deals and give them the confidence to negotiate the key terms. Licensing is not just relevant for the ‘big ticket’ tech transfer deals; licence terms are often included in research funding agreements, collaboration agreements, etc.
Paul is a solicitor and a Partner at Anderson Law LLP, a niche firm of commercial/IP solicitors based in Oxfordshire. Paul advises on a wide variety of commercial agreements focussing on transactional work within the IT, life sciences and university sectors. His clients include leading UK universities and an international IT/telecoms company. Paul is listed in Chambers & Partners as a leading UK lawyer in the field of Intellectual Property and is a contributor to a number of Anderson Law’s publications on intellectual property and commercial law, most recently Technology Transfer (3rd Ed, Bloomsbury, 2010).
Iain is Head of Cambridge Enterprise’s Life Sciences team at the University of Cambridge where he and his team work in fields as diverse as therapeutics, diagnostics, biofuels, IVF, epigenetics and agritech. CE’s portfolio of products includes alemtuzumab (Sanofi), breast cancer markers (Brevagen) and mouse touch screen chambers (Campden Instruments). Recent spin-outs include Morphogenix, Mission Therapeutics, Cambridge Epigenetix, XO1 Therapeutics (sold to Janssen), Z-factor, Phoremost, and Storm Therapeutics. Iain led discussions with GSK in respect of the University of Cambridge–GSK open innovation drug discovery initiative based at the SBC and was the Cambridge lead for the Apollo Therapeutics Fund. Iain has been an active trainer for Praxis Courses since 2004.